Loading
Led PROSPER and the PROfound survival analysis, and settled the intermittent hormone therapy question with SWOG 9346.
Maha Hussain led SWOG 9346, the trial that showed intermittent androgen deprivation is not non-inferior to continuous therapy in metastatic prostate cancer, and was principal investigator of PROSPER (enzalutamide in non-metastatic CRPC) and first author of the PROfound overall survival report establishing olaparib in HRR-mutant disease. She chairs the SWOG GU committee's prostate programme.
| Title | Journal | Year |
|---|---|---|
| Survival with olaparib in metastatic castration-resistant prostate cancer (PROfound) | NEJM | 2020 |
| Intermittent versus continuous androgen deprivation in prostate cancer (SWOG 9346) | NEJM | 2013 |
| PROSPER: enzalutamide in men with non-metastatic castration-resistant prostate cancer | New England Journal of Medicine | 2018 |
Shares PARP, Androgen receptor, PARP inhibitors, BRCA1 / BRCA2 (HRD) and the tag prostate.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tag prostate.
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tag prostate.
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares PARP, PARP inhibitors, BRCA1 / BRCA2 (HRD) and the tag parp.
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tag prostate.